40 results about "Atrophic spinal cord" patented technology

The present invention relates to combinations and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorder, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury, based on Baclofen and Acamprosate combination.

The invention relates to the use of angiogenin, or a fragment or variant thereof, to treat diseases or conditions characterised by neuronal injury or death, or axonal degeneration, especially neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). The invention also describes a plurality of mutations of the human angiogenin gene which are associated with a neurodegenerative disease phenotype, and particularly a ALS phenotype. Also described is a method of assessing whether an individual is afflicted with, or generically predisposed to develop, a disease or condition characterised by neuronal injury or death, or axonal degeneration.

Peptides derived from anti-inflammatory cytokines, such as IL-10, are disclosed for use in treatment of neurodegenerative diseases and neuropathic pain indications, including Alzheimer's disease, Amyotrophic Lateral Sclerosis, Multiple Sclerosis, Parkinson's disease and trigeminal neuralgia.

L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and / or prevention of protein aggregation / tangles / plaques and diseases associated with protein aggregation / tangles / plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates for treatment, amelioration and / or prevention of protein aggregation / tangles / plaques and diseases associated with protein aggregation / tangles / plaques. In particular, treatments and uses for L-serine, L-serine precursors, L-serine derivatives and L-serine conjugates include Alzheimer's disease (AD), Parkinson's disease, Amyotrophic Lateral Sclerosis (ALS), and Huntington disease (HD).

The invention relates to a combination drug therapy composition used for treating amyotrophic lateral sclerosis and a preparation method and use thereof. The composition includes chlorogenic acid, vitamin E, vitamin C, coenzyme Q10, creatine phosphate sodium and a pharmaceutically acceptable carrier, wherein the chlorogenic acid, the vitamin E, the vitamin C, the coenzyme Q10, and the creatine phosphate sodium are unit preparations having same or different specifications and are administrated separately or together. After combination of the chlorogenic acid, the vitamin E, the vitamin C, the coenzyme Q10, and the creatine phosphate sodium, unexpected synergistic treatment effect on the amyotrophic lateral sclerosis is achieved, and therefore, the composition used for treating the amyotrophic lateral sclerosis and having excellent treatment effect is provided, and the composition can obviously delay disease progression of the amyotrophic lateral sclerosis.

Provided is a cell therapeutic agent for treatment of neurological disorders, comprising skin-derived progenitor cells (SPCs). More specifically, the present invention provides a cell therapeutic agent for treatment of neurological disorders, comprising skin-derived progenitor cells (SPCs) isolated from skin tissues and a method for differentiation of the skin-derived progenitor cells (SPCs) into neural cell lineages. The cell therapeutic agent in accordance with the present invention is therapeutically effective for the treatment of the neurological disorders and diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease and Amyotrophic Lateral Sclerosis (ALS) caused by neural injury, and neurological deficits due to cerebral apoplexy, ischemia and spinal cord injury. Further, the present invention enables transplantation of autologous cells to thereby minimize adverse side effects.

The present invention relates to compositions and methods for the treatment of neurological disorders related to glutamate excitotoxicity and Amyloid β toxicity. More specifically, the present invention relates to novel combinatorial therapies of Multiple Sclerosis, Alzheimer's disease, Alzheimer's disease related disorders, Amyotrophic Lateral Sclerosis, Parkinson's disease, Huntington's disease, neuropathic pain, alcoholic neuropathy, alcoholism or alcohol withdrawal, or spinal cord injury.

Some aspects of the invention provide for a method of treating Alzheimer's Disease, Mild Cognitive Impairment, Frontotemperal Dementia, Amyotrophic Lateral Sclerosis and / or Multiple Sclerosis using polyunsaturated fatty acids which are modified in certain positions to attenuate oxidative damage by Reactive Oxygen Species (ROS) and / or suppress the rate of formation of reactive products and toxic compounds.

The present invention provides a method for providing neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection, which comprises periodically administering to the subject a certain amount of glatiramer acetate and a certain amount of 2-amino-6 - Trifluoromethoxybenzothiazole, wherein said amount is effective to provide neuroprotection to said subject's central or peripheral nervous system when taken together. The present invention also provides a package comprising glatiramer acetate, 2-amino-6-trifluoromethoxybenzothiazole, and a composition for use together to provide neuroprotection to the central or peripheral nervous system of a subject in need of such neuroprotection. Neuroprotective Instructions for Use. Furthermore, the present invention provides a pharmaceutical composition comprising an amount of glatiramer acetate and an amount of 2-amino-6-trifluoromethoxybenzothiazole, wherein said amounts are effective to provide for Neuroprotection of the subject's central or peripheral nervous system. The present invention also provides a pharmaceutical combination comprising a certain amount of glatiramer acetate and a certain amount of 2-amino-6-trifluoromethoxybenzothiazole in separate dosage forms, the combination is effective for providing Neuroprotection of the central or peripheral nervous system. Additionally, the combination therapy may be used to treat a subject afflicted with multiple sclerosis or a subject afflicted with amyotrophic lateral sclerosis.

Methods of selecting a subject for treatment of amyotrophic lateral sclerosis (ALS) and methods of treatment for subjects having ALS or at risk of developing ALS are provided. The method of selecting subjects for treatment includes obtaining a biological sample from the subject, where the sample is obtained from the subject's gastrointestinal tract or skeletal muscle. The method further includes measuring a biomarker in the subject's sample and selecting the subject for treatment of ALS when the biomarker measurement in the subject's sample is lower or higher relative to a control measurement.